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Objective: We analyzed the long-term morbidity and mortality of our
experience with combined mitral-aortic surgery, as well as their determi-
nants. Methods: Among 2109 consecutive patients undergoing valve opera-
tions, 200 had mitral-aortic valve procedures with at least implantation of
a mechanical prosthesis: 163 of 200 (81.5%) patients had double valve
replacement and 37 of 200 (18.5%) had mitral valve repair and aortic valve
replacement. All mechanical valves were bileaflet prostheses. Preopera-
tively, 171 of 200 (85.5%) patients were in New York Heart Association class
III-IV. Event-free survivals were determined by means of the Kaplan-Meier
method and determinants of survivals with the Cox proportional hazards
model (p < 0.05) entering 39 preoperative and perioperative factors.
Follow-up was complete for 96% of the patients (192/200). Results: Overall
survivals at 5, 10, and 15 years were 88.5% 6 0.55%, 73.5% 6 4%, and 53.3%
6 8.9%, and rates of freedom from valve-related mortality were 92.9% 6
1.5%, 85.8% 6 3.5%, and 85.8% 6 3.5%. The rates of freedom from
permanent valve-related impairment were 91.5% 6 1.7%, 85.4% 6 3.5%,
and 79.3% 6 6.7%, and those from all valve-related mortality and morbidity
were 74.1% 6 2.3%, 53.8% 6 5%, and 49% 6 5.6%. At last follow-up, 90%
(139/154) of the survivors were in New York Heart Association class I-II.
Left ventricular ejection fraction less than 50%, age older than 70 years,
and preoperative ventricular arrhythmias were independent risk factors for
valve-related late deaths. Diabetes, ejection fraction less than 50%, and
coronary artery disease were independent determinants of all valve-related
events. Conclusions: Functional results of survivors of combined mitral-
aortic surgery are excellent. However long-term valve-related morbidity and
mortality are substantial. In the patient population studied, the predictors
are determined by patient-related factors, mainly myocardial factors, but
not by valve-related factors. (J Thorac Cardiovasc Surg 1998;115:1298-309)
During the past 15 years, bileaflet prostheses,especially the St. Jude Medical prostheses (St.
Jude Medical, Inc., St. Paul, Minn.), have been the
cardiac valve of choice at many centers and have
represented a valuable alternative to other available
mechanical and bioprosthetic devices. The results of
bileaflet prosthesis with single valve surgery have
been extensively reported.1 The late outcome ($10
years) after combined surgery of the aortic and the
mitral valves is less well known. Most authors have
associated the results of their mitral-aortic opera-
tions with those of isolated aortic or mitral valve
operations.2-9 Few have focused critically on this
subset.10-12
This study reports the long-term results of our
experience with simultaneous surgery of the aortic
and mitral valve with the implantation of at least one
bileaflet prosthetic valve, as well as the determinants
of adverse events.
Patients and methods
Patient population. All the patients who underwent
combined aortic and mitral valve operations with the
implantation of at least one bileaflet prosthetic valve
between March 1981, when we first used bileaflet pros-
thesis for a double valve replacement, and April 1996 were
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reviewed. Patients with concomitant coronary artery by-
pass operations and other valve procedures were included
in the study. The study comprised 200 such patients
among a total of 2109 patients having undergone valvular
surgery during the same time period. The main clinical
characteristics of the patient population are shown in
Table I. The cause of valvular disease was rheumatic in
110 patients (55%), degenerative in 42 patients (21%),
active endocarditis in 19 patients (9.5%), congenital in 16
patients (8%) and long-term complications of previous
valve operations in 13 patients (6.5%).
Surgical procedure. All the operations were performed
with the patient supported by standard cardiopulmonary
bypass, with moderate hemodilution and moderate hypo-
thermia (28° C). Cold crystalloid cardioplegia and topical
pericardial cooling were used for myocardial protection.
Valve implants were secured into position with six running
2-0 polypropylene sutures for the aortic valve and eight
for the mitral valve. When used, mitral valve repair
techniques were those described by Carpentier.13 Mitral
valve repair was introduced in our institution in 1985.
One hundred sixty-three patients (81.5%) had double
heart valve replacement with mechanical prostheses. Thir-
ty-seven patients (18.5%) had mitral valve repair and
aortic valve replacement. All the mechanical valves were
of the bileaflet type: 310 St. Jude Medical valves (171
aortic and 139 mitral), 34 CarboMedics valves (19 aortic
and 15 mitral) (Sulzer Carbomedics Inc., Winterthur,
Switzerland), and 19 ATS valves (10 aortic and 9 mitral)
(Advancing The Standard Medical Inc., Minneapolis,
Minn.). Associated procedures were performed in 38
patients (19%): 22 tricuspid operations (11%) (20 repairs
and 2 bileaflet prostheses) and 18 coronary artery bypass
grafts (9%).
Postoperative anticoagulation. Anticoagulation ther-
apy with continuous intravenous heparin (10,000 units in
24 hours) was started 12 hours after the operation. Oral
anticoagulation with acenocoumarol was instituted 24
hours after the operation and heparin was continued until
the target international normalized ratio was brought to a
value of 3 to 4. After hospital discharge, the general
practitioner was responsible for anticoagulation control.
Follow-up. All the follow-up data were collected over a
2-month period. Information was obtained by double
phone interviews with all living patients and with either
the family or general practitioner to increase the accuracy
of the follow-up. Data for the deceased patients were
collected from the family and the general practitioner.
Contact was lost with eight patients. Follow-up was 96%
complete with double interviews in all survivors. This
represents 1144 patient-years with a mean of 5.7 years per
patient, a minimum of 6 months, and a maximum of 15.2
years. All traced patients were evaluated for valve-related
complications and New York Heart Association class at
the time of follow-up and reoperation. Long-term fol-
low-up echocardiographic data were obtainable in 120 of
the 164 survivors (73%) who had routine echocardio-
graphic examinations.
Definitions. Complications were defined in accordance
with the published guidelines for reporting valve-related
morbidity and mortality after cardiac valvular operation.14
They included structural deterioration, nonstructural dys-
function, valve thrombosis, embolism, bleeding event,
prosthetic valve endocarditis, reoperation, valve-related
mortality, permanent valve-related impairment, and all
valve-related morbidity and mortality. To detect as many
transient ischemic accidents as possible, we asked the
patients whether they had had blurred or double vision,
difficulty in speaking or moving a limb, facial asymmetry,
loss of sensitivity, sudden gait disturbance, dizziness, or
transient loss of memory. Sudden death was defined as a
nonaccidental witnessed or unwitnessed death of a person
for whom time of death was unexpected and mode of
death was unexplained. Because of the controversy about
the justification in considering sudden death as part of a
valve-related death,15 the results for valve-related death
and combined valve-related mortality and morbidity are
presented both including and excluding cases of sudden
death.
Statistical analysis. All data were entered into a
spreadsheet (Microsoft Excel 4, Microsoft Corporation,
Redmond, Wash.) and analyzed with StatView 4.5 statis-
tical software for Macintosh (Abacus Concepts Inc.,
Berkeley, Calif.). The different late valve-related events
were expressed in linearized form (percent per patient-
year) for which all events were considered. So that the
long-term results could be described in accordance with
the guidelines,14 actuarial curves for mortality and com-
plications were obtained by the Kaplan-Meier method and
reported with the standard error of the estimate. For this
analysis, only the first event of each type of complication
was considered. Univariate comparisons of subgroups
were made with the log-rank test. Variables with a p ,
0.05 were entered into the Cox’s proportional hazard
model to identify independent prognostic factors. When
some covariates were highly correlated, we included the
most significant one. Results of the multivariate analysis
are given with estimates of the b coefficient and as odds
Table I. Clinical characteristics of the patient
population
Mean 6
SD (range)
Patients
No. %
Age (yr) 56.2 6 13.6
(16-81)
Female 105 52.5
NYHA functional class
I 1 0.5
II 33 16.5
III 66 33
IV 100 50
Arrhythmias
AF 114 57
Ventricular arrhythmias 9 4.5
CAD 17 8.5
Diabetes 12 6
Creatinine $120 mmol/L 36 18
Alcoholism 11 5.5
Urgent operation 25 12.5
AF, Atrial fibrillation; CAD, coronary artery disease; NYHA class, New
York Heart Association class; 6SD 5 1 standard deviation.
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ratio (95% confidence interval), with the significance level
p value for each variable. The events tested were embo-
lisms, overall mortality, valve-related mortality, sudden
death, and overall valve-related events. Bleeding events
and prosthetic valve thromboses were not tested because
they are most likely due to excessive or insufficient oral
anticoagulation, and blood coagulation tests were not
available at the time of the event in most patients.
Hemolysis and nonstructural valve failure were not ana-
lyzed because they were not formally screened. Endo-
carditis was not tested because too few events occurred.
The list of the 39 screened variables is given in Appen-
dix Table I.
Results
Survival. Ten patients died within 1 month of the
operation, yielding a 30-day mortality of 5%. Eight
patients died of a cardiac nonvalvular cause, six of
them of pump failure. One death was considered
valve-related: a myocardial infarction on the third
postoperative day, without coronary artery disease
on catheterization. One death was noncardiac: a
ruptured intracranial mycotic aneurysm. There
were 26 late deaths, for a linearized incidence of
2.3%/pt-yr. Fourteen deaths (54%) were valve-
related, 8 deaths (31%) were cardiac non-valve-
related, and four deaths (15%) were noncardiac.
Actuarial survivals at 5, 10, and 15 years are
depicted in Fig. 1.
Valve-related complications
Structural deterioration. Structural deterioration
did not occur in any patient in this study.
Nonstructural dysfunction. Nonstructural dysfunc-
tion occurred in two cases. One patient required a
second aortic valve replacement because of a pan-
nus ingrowth. One patient with an important aortic
paravalvular dehiscence refused a reoperation and
is still alive at 5 years. Eight symptom-free patients
had incidental minor paravalvular leaks discovered
by echocardiography, and these were not considered
to be complications. All the paravalvular leaks were
on the aortic valve. The linearized rate for nonstruc-
tural dysfunction was 0.2%/pt-yr, and the 5-, 10-,
and 15-year actuarial event-free rates were 99.3% 6
0.7%, 97.7% 6 1.7%, and 97.7% 6 1.7%.
Thromboembolism. Valve thrombosis occurred in
two patients. One patient died shortly after her
admission in a comatose state. The autopsy showed
thrombosis of both mitral and aortic prosthetic
valves with massive cerebral embolism. The other
patient with poor compliance had thrombosis of a
tricuspid prosthetic valve and underwent successful
thrombolysis. Both patients were receiving inade-
quate anticoagulation with a decreased prothrombin
time ratio (almost 1). The linearized rate was 0.2%/
pt-yr and the 5-, 10-, and 15-year actuarial event-free
Fig. 1. Actuarial overall survival. SE, Standard error of the estimate; N. PT., number of patients.
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rates were 99.1% 6 0.8%, 99.1% 6 0.8%, and
92.9% 6 6%.
Thirty embolisms were documented in 25 pa-
tients, for a linearized rate of 2.6%/pt-yr. Five
patients had an ischemic stroke, one of which was
fatal. Twelve patients had transient ischemic attacks.
Five patients had repeated cerebral ischemic events:
two without sequel, two with persistent neurologic
deficit, and one fatal. That patient died of cerebral
infarctions because anticoagulation had to be lev-
eled off owing to severe hemorrhaging after maxil-
lary sinus drainage. Systemic embolism was re-
corded in three patients: two myocardial infarctions
and one occlusion of a peripheral artery to a limb.
Both myocardial infarctions, occurring on the third
postoperative day and 1 year after the operation,
respectively, were considered valve-related because
preoperative angiography did not show any sign of
coronary artery disease and no other reason such as
myxoma or atherosclerosis of the ascending aorta
could be involved. The frequency of valve-related
impairment and death was 33% (10/30) and 10%
(3/30), respectively. The 5-, 10-, and 15-year actuar-
ial embolism-free rates are shown in Fig. 2.
Table II shows variables found to be significant in
univariate and multivariate analysis of embolism.
Notably, mitral valve plasty associated with aortic
valve replacement did not result in significantly less
embolism than double heart valve replacement. The
actuarial event-free rates at 5 and 10 years were
96% 6 3.9% and 82.3% 6 13.1% for patients with
mitral valve plasty versus 88.9% 6 3% and 72.7% 6
5.7% for patients with mitral valve replacement (p 5
0.176).
Bleeding events. A total of 30 bleeding events
occurred in 27 patients. Two patients had intracra-
nial hemorrhage, and both incurred permanent def-
icits. Twenty-five patients had 27 extracranial hem-
orrhages, and two of them died. The linearized rate
for bleeding events was 2.6%/pt-yr, and the 5-, 10-,
and 15-year actuarial event-free rates are depicted
in Fig. 3. The incidences of valve-related impair-
ment and death were 13% (4/30) and 10% (3/30),
respectively.
Prosthetic valve endocarditis. No cases of early
prosthetic valve endocarditis developed, but late
endocarditis developed in two patients. Both had
double valve replacement with bileaflet mechanical
prostheses. One patient underwent a sigmoidectomy
48 months after heart valve surgery because of
volvulus and died 20 days after the operation of a
Candida sepsis. Postmortem examination showed
vegetations on both prosthetic valves and a massive
cerebral infarct. The other patient presented 2 years
after heart valve replacement with bronchopneumo-
nia and left-sided cardiac failure with a moderate
Fig. 2. Actuarial freedom from embolism. SE, Standard error of the estimate; N. PT., number of patients.
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mitral paravalvular leak. Although blood cultures
were not positive, the diagnosis was endocarditis
inasmuch as echocardiograms taken at 6 months and
1 year showed no leak. The patient finally under-
went closure of the increasing leak after a 6-week
course of antibiotics. There was no sign of technical
failure during the operation. The linearized rate for
prosthetic valve endocarditis was 0.2%/pt-yr and the
5- and 15-year actuarial event-free rates were both
98.5% 6 1%.
Valve-related consequences
Reoperation. Two patients required reoperation
involving the implanted valves. The first patient had
a second aortic valve replacement because of pannus
ingrowth, and the second had closure of an increasing
endocarditic paravalvular leak. The linearized-rate for
reoperation was 0.2%/pt-yr and the 5-, 10-, and 15-year
actuarial event-free rates were 99.3% 6 0.7%, 97.7%
6 1.7%, and 97.7% 6 1.7%, respectively.
Valve-related mortality. The 14 valve-related
deaths included eight unexpected sudden deaths,
two bleeding events, two cerebral embolisms, one
case of prosthetic valve thrombosis, and one case of
fungal endocarditis. The cause of death in six of
seven (86%) patients with established etiology was a
thromboembolic or a bleeding event. The linearized
rates for valve-related mortality were 1.2%/pt-yr and
0.5%/pt-yr when sudden deaths are excluded. The
respective actuarial event-free rates at 5, 10, and 15
years with and without sudden deaths are shown in
Fig. 4.
Table II shows variables found to be significant in
univariate and multivariate analysis of valve-related
mortality and sudden deaths. Here again, mitral
valve plasty associated with aortic valve replacement
did not result in a significantly lower incidence of
valve-related death than double heart valve replace-
ment. The actuarial event-free rates at 5 and 10
years were 88.2% 6 5.6% and 82.3% 6 7.7% for
patients with mitral valve plasty versus 88.7% 6
2.7% and 73.4% 6 5% for patients with mitral valve
replacement (p 5 0.872).
Permanent valve-related impairment. Overall, 18
patients had 19 valve-related events with subsequent
Table II. Risk factors for embolism, overall mortality, valve-related death, sudden death, and all valve-related
events
Event Variables
Univariate analysis
by log-rank test
Cox’s proportional hazard model
(independent risk factors)
p Value b OR 95% CI p Value
Embolism Diabetes 0.001 1.741 5.7 1.8-17.4 0.002
Associated CAD 0.011 1.442 4.2 1.4-12.9 0.015
All deaths Age . 70 yr 0.001 1.285 3.6 1.2-10.9 0.022
LVEF , 50% ,0.001 1.009 2.7 1.1-6.6 0.023
Ventricular arrhythmias 0.007
Urgent operation ,0.001
Diabetes 0.002
Creatinine $ 120 umol/L 0.004
Associated CAD 0.009
RAP $8 mm Hg 0.011
Cardiac index # 2.5 L/min 0.048*
Valve-related death including sudden death LVEF ,50% ,0.001 2.171 8.7 2.8-27.4 ,0.001
Age . 70 yr 0.005 2.058 7.8 1.9-33 0.005
Ventricular arrhythmias 0.002 2.251 9.5 1.4-62.5 0.019
Urgent operation 0.02
Associated CAD 0.001
Valve-related death without sudden death LVEF , 50% 0.01
Associated CAD 0.023
Sudden death Ventricular arrhythmias 0.004
NYHA class IV 0.02
All valve-related events Diabetes 0.008 1.069 2.9 1.3-6.5 0.009
LVEF , 50% 0.016 0.745 2.1 1.1-3.9 0.016
Associated CAD ,0.001 0.795 2.2 1-4.7 0.038
Age . 70 yr 0.01
OR, Odds ratio; CI, confidence interval; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; RAP, right atrial pressure; NYHA, New York
Heart Association.
*Reason for excluding variables from Cox’s model is given in the paragraph on statistics.
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permanent functional deficit. These events in-
cluded nonstructural dysfunction (n 5 1), valve
thrombosis (n 5 2), embolic episodes (n 5 10),
bleeding events (n 5 4), and endocarditis (n 5 2).
The linearized rate for permanent physical im-
pairment was 1.7%/pt-yr and the 5-, 10-, and
15-year actuarial event-free rates are depicted in
Fig. 5. A thromboembolic or bleeding event was
the cause of 16 of 19 (89%) permanent valve-
related impairments.
All valve-related morbidity and mortality. All valve-
related morbidity and mortality included 85 events
in 62 patients, or a linearized rate of 7.4%/pt-yr.
When sudden deaths were excluded, there were 77
events in 54 patients, for a linearized rate of 6.7%/
pt-yr. The 5-, 10-, and 15-year actuarial valve-related
event-free rates with and without sudden death are
shown in Fig. 6. Thromboembolism or bleeding was
the cause of 60 of 77 (78%) events.
Clinical condition. Comparison of New York
Heart Association functional class before operation
and by the latest date of follow-up in the 164
long-term survivors showed that 133 (81%) of the
survivors were in class III or IV before the opera-
tion, and at follow-up 145 (88%) of the survivors
were in functional class I or II. One hundred
forty-three patients (87%) had had improvement in
their functional class by at least one stage at the time
of follow-up.
Discussion
Operative risk of patient candidates for multival-
vular operations has already been shown to be no
longer substantially higher than that in patients with
isolated valve replacement.16 However, studies fo-
cusing on the long-term results of this operation in
the bileaflet prosthesis area have included no more
than 100 patients, and the highest total follow-up
was 309%/pt-yr.10-12 The present study provides the
long-term results of 200 patients operated on over a
period of 15 years with a total follow-up of 1144
patient-years.
The linearized and actuarial event-free rates for
embolism are in accordance with the findings of the
literature. Table III presents the range of linearized
rate of valve-related events associated with double
valve surgery in 11 studies on bileaflet prostheses.
Eight of these studies have reported the results of
double valve surgery together with those of single
valve surgery. When one considers the overall lin-
earized rate for embolism in the latter studies,
ranging from 0.5% to 3.5%, our 2.6% still compares
favorably. This confirms the low thrombogenesis of
bileaflet valves, even in the scenario of double heart
valve surgery. This statement is moderated by two
considerations. First, most emboli are cerebral and
because the brain receives only 14% of the total
cardiac output, this is probably an underestimation
of the true embolic incidence. Second, Horstkotte
Fig. 3. Actuarial freedom from bleeding event. SE, Standard error of the estimate; N. PT., number of patients.
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and associates17 performed the only prospective
long-term study of patients with St. Jude Medical
prostheses using extremely conservative criteria for
defining thromboembolism and bleeding complica-
tions to identify all possible complications irrespective
of the severity of the event. They found an unexpected
linearized rate of 5.3%/pt-yr of thromboembolism with
double heart valve replacement. This indicates that the
rates in retrospective studies are probably underesti-
mated. On the other hand, results of multivariate
analysis showed diabetes and associated coronary ar-
tery disease as independent risk factors for emboli.
This suggests that emboli not linked with heart valves
must exist, because both risk factors can be considered
surrogates for atherosclerosis, a systemic disease also
involving the precerebral arteries. Moreover, none of
the valve-related risk factors were found to be signifi-
cant, even on univariate analysis. In particular, patients
with mitral valve plasty and aortic valve replacement
did not fare significantly better than patients with
double heart valve replacements.
Bleeding together with embolism were the most
frequent valve-related complications. Inadequate
anticoagulation has been recognized to be the main
reason for their occurrence.7 Our linearized inci-
dence is in the range of those reported in the
literature (Table III); however, as for embolism this
range is wide. The most likely explanation lies in the
method of selection of bleeding events. According
to the guidelines,14 we included any episode of
internal or external bleeding that causes death,
stroke, precipitates surgery or hospitalization, or
requires transfusion. Therefore, in cataloging all the
events that required a hospitalization, we also in-
cluded benign events treated on an outpatient basis.
This feature also explains the non-neurologic nature
of most bleeding events. The remark concerning the
weakness of retrospective study for registering em-
bolism is also valid for bleeding events, inasmuch as
Horstkotte and colleagues17 found, prospectively, a
linearized incidence of hemorrhage of 6.1%/pt-yr in
patients with double valve replacement.
Our experience with valve thromboses supports
the findings of other series, including single valve
replacement3, 7: it is a life-threatening complication,
with a 50% mortality rate, and is due to inadequate
anticoagulation. Notably, we had only two cases of late
endocarditis with a linearized incidence of 0.2%/pt-yr.
None of the cases of endocarditis occurred in the
group of patients with active endocarditis as a surgical
indication. This suggests that a higher quantity of
prosthetic material does not mean a higher risk of
Fig. 4. Actuarial freedom from valve-related death with sudden death being included or excluded from
valve-related death. SE, Standard error of the estimate; N. PT., number of patients.
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infectious complications. Structural deterioration re-
sulting in mechanical failure of the prosthesis did not
occur. The review of the literature of Orsinelli and
colleagues18 reported six isolated cases of leaflet em-
bolization and one case of leaflet fracture.
Because we perform valve implantation with run-
ning sutures, we wondered whether this technique
would account for a higher rate of periprosthetic
leak. We had only one patient with significant
paravalvular leak. Incidental minor leak found at
routine echocardiography was recorded in eight
patients among 120 survivors (6.7%) who underwent
routine echocardiography. Some authors found a
predominance of leakage in the mitral position.6, 19
We found it exclusively in the aortic position. This
could be due to the better visualization of the aortic
valve on transthoracic echocardiography and the
strain on the supporting structure of this valve in
relation to the high pressure gradient.
Parallel to the findings of the literature,6, 7, 10, 11, 20
thromboembolism and bleeding events are still the
most frequent and the most dangerous valve-related
complications in terms of permanent valve-related
event and survival: 74% (16/19) of valve-related
impairments and 86% (6/7) of valve-related deaths
with an established cause were due to a thrombo-
embolic or bleeding event. These results highlight
the hazards and limitations of anticoagulation in
patients with mechanical prostheses and underline
the fact that, although bileaflet prostheses compare
most favorably with other substitute valves, the ideal
valve has yet to been found. The inverse relationship
between the incidence of thromboembolism and
bleeding events has been previously recognized.21
The similar incidence of embolic and bleeding
events would suggest that our level of anticoagula-
tion is an adequate balance between excessive and
insufficient anticoagulation in double heart valve
surgery. Recently, however, some authors22 have
suggested that a low international normalized ratio
caused only a marginal increase in the rate of
embolism but a highly significant decrease in the
rate of bleeding. No large-scale results on double
heart valve surgery have so far been reported, and
guidelines for anticoagulation in double heart valve
surgery are still lacking.23
The actuarial survival of patients free of valve-
related mortality at 10 years is comparable with
those of Smith,8 De Luca,9 and their coworkers for
St. Jude Medical and CarboMedics valves, respec-
tively. Risk factors associated with valve-related
mortality by multivariate and by univariate analysis
are all patient-related factors. Significant determi-
nants include left ventricular ejection fraction less
Fig. 5. Actuarial freedom from permanent valve-related impairment. SE, Standard error of the estimate;
N. PT., number of patients.
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than 50%, age older than 70 years, and ventricular
arrhythmias. Notably, the first two factors are also
determinants of deaths of all causes. This is in
keeping with coronary artery disease and coronary
artery bypass grafting reported as the strongest
predictor of valve-related mortality in the series of
Czer,4 Ibrahim,6 and their associates, respectively.
As with embolism, no valve-related factor is in-
volved and even mitral valve repair has no bearing
on valve-related outcome. Mitchell and colleagues24
clearly demonstrated that the valve-related compli-
cations were more importantly related to patient-
related factors, and Rahimtoola25 emphasized that
“the results of valve surgery are dependent on many
factors; the type of surgery or valve replacement
device is only one variable that influences the re-
sults.” Moreover, Stephenson and coworkers20 re-
ported no influence of four different types of valve
Fig. 6. Actuarial freedom from all valve-related events with sudden death being included or excluded from
valve-related death. SE, Standard error of the estimate; N. PT., number of patients.
Table III. Ranges of linearized rates of valve-related events after double valve replacement with bileaflet
prostheses (St. Jude Medical and CarboMedics) in 11 retrospective studies of the literature
First author Valve type
No. of
patients
Mean
FU (yr)
Embolism
(%/pt-yr)
Bleeding
(%/pt-yr)
Valve
thrombosis
(%/pt-yr)
Endocarditis
(%/pt-yr)
Paravalvular leak
(%/pt-yr)
All valve-related
events (%/pt-yr)
Burckhardt2 SJM 81 2.6 1.1 — — — — —
Kinsley3 SJM 126 3 1.7 — 0.85 0.01 — 4.8
Czer4 SJM 74 3.3 2 3.1 0 0.3 0 6.1
Nakano5 SJM 223 0.5-12 0.79 0.1 0 0.2 0.2 1.28
Ibrahim6 SJM 70 4.2 5 2.1 0.001 1 1.26 —
Baudet7 SJM 132 9.7 1.6 1.01 0.7 0.3 0.1 3.74
Smith8 SJM 64 5 0.3 0.3 0 0.3 0.3 —
de Luca9 CarboMed 76 1.5 0.3 0.65 — — — —
Armenti10 SJM 92 2.8 4.6 1.2 0 2.5 — 9.1
Arom11 SJM 100 5 1.29 0 0.32 0 0.32 —
Copeland29 CarboMed 144 2.5 3.1 1.24 0 1.55 1.24 —
CarboMed, CarboMedics valve; Mean FU (yr), mean time of follow-up in years, except for the study of Nakano and associates, in which only the range was
mentioned; SJM, St. Jude Medical valve.
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prostheses on the morbidity and mortality in com-
bined aortic and mitral surgery, while in most pa-
tients late mortality and morbidity continued to be
cardiac in nature or related to anticoagulant ther-
apy.
A controversial point remains in the inclusion of
sudden death in the valve-related deaths. The sig-
nificant risk factors on univariate analysis were
known preoperative ventricular arrhythmias and
associated coronary artery disease. Although sug-
gestive, univariate analysis does not prove a direct
relationship between arrhythmias and sudden death.
Here again, none of the valve-related factors have
been identified as risk factors. This finding is in
agreement with two recent autopsy studies question-
ing the value of classifying sudden death as valve-
related death. Rooney and colleagues26 showed in
48 autopsies after sudden deaths with the Medtronic
Hall valve (Medtronic, Inc., Minneapolis, Minn.)
that 90% of deaths were unrelated to the prosthesis,
and Burke and coworkers27 found among 37 pa-
tients with sudden death that more than half of the
deaths were due to cardiac hypertrophy and athero-
sclerosis, hypothesizing a relationship with ventric-
ular arrhythmia.
For survivors, the functional results were excel-
lent, with most patients being in New York Heart
Association class I or II at the time of follow-up.
This confirms the functional improvement with mi-
tral-aortic valve surgery to be more or less the same
as with isolated valve surgery. Importantly, despite
the overall good performance of bileaflet valves, the
low incidence of freedom from all valve-related
complications at 15 years (49% 6 5.6%) reminds us
that patients who undergo prosthetic valve replace-
ment do not have a normal outlook but have instead
undergone substitution of one disease (prosthetic
valve) for the original disease (native valve). How-
ever, when only valve-related complications with
permanent impairment are considered, the freedom
from such complications at 15 years is much higher
(79.3% 6 6.7%).
Limitations of the study. The major limitation of
the present study is that most information was
collected retrospectively, a process that may reduce
the validity of some data. However, particular atten-
tion was paid to the methods used in the follow-up.
Information was collected twice for each patient.
The general practitioner was interviewed, as well as
the patient or his or her family. We used the
personal interview, because its reliability has been
shown to be superior to questionnaires sent by
mail.28 In view of this and the high rate of follow-up,
we still consider our data conclusive. Another limi-
tation is the inclusion of patients with different types
of mechanical valve prostheses. Nevertheless, all
three types of valves used are bileaflet prostheses
built on the same principle29; thus the incidence of
valve-related events is likely not to be significantly
altered by the type of prosthesis. This is supported
by the findings of a recent prospective study com-
paring St. Jude Medical versus CarboMedics valves
in mitral and multiple valve replacement operations:
there were no distinguishing performance character-
istics with regard to thromboembolic events.30
Moreover, in a study of our group, the ATS valve
showed hemodynamic indices that were comparable
with available results of other bileaflet and tilting-
disc prostheses.31 Risk factor analysis did not show
valve type as a significant risk factor; thus the
recruitment of consecutive patients appears to be
more important than the recruitment of one type of
valve. Clotting parameters at the time of embolic or
bleeding events were unavailable in most patients.
This lack is a major limitation in most studies of the
literature. General practitioners should be encour-
aged to document the anticoagulation status at the
time of any thromboembolic or bleeding event oc-
curring in any patient after heart valve surgery, as
well as on a regular basis during the follow-up.
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Appendix Table I. Variables (n 5 39) screened by univariate analysis for mortality and complications
Variables Categories
Preoperative
Sex Male/female
Age (yr) $70/,70
BSA (m2) #1.7/.1.7
Diabetes Present/absent
Hypertension Present/absent
COPD Present/absent
Angina pectoris Present/absent
Signs of CHF Present/absent
Peripheral vascular disease Present/absent
Prior myocardial infarction Present/absent
Prior cerebrovascular accident Present/absent
NYHA functional class NYHA I-II/III-IV and I-III/IV
AF Present/absent
Ventricular arrhythmias Present/absent
Creatinine (mmol/L) $120/,120
Alcoholism Present/absent
Previous heart surgery Present/absent
CT ratio $0.6/,0.6
ECG LVH Present/absent
Active endocarditis Present/absent
Surgical priority Elective/urgent/emergency
RAP (mm Hg) $8/,8
PAPs (mm Hg) $60/,60
PAPm (mm Hg) $30/,30
PWCP (mm Hg) $20/,20
LVDEP (mm Hg) $10/,10
LVDEVI (ml/m2) $100/,100
Cardiac index (L/m2/min) #2.5/.2.5
LVEF (%) #50/.50
Physiopathologic anomaly Mitral regurgitation/mitral stenosis/mixed mitral disease/aortic regurgitation/
aortic stenosis/mixed aortic disease
Etiology of valve disease Rheumatic/endocarditic/degenerative/congenital/previous prosthetic valve
Associated tricuspid valvulopathy Present/absent
Associated CAD Present/absent
Operative and postoperative
Type of valve surgery double heart valve replacement/mitral plasty and aortic valve replacement
Type of valve prosthesis St. Jude Medical/CarboMedics/Advance The Standing
Aortic prosthetic size (mm) $23/,23
Mitral prosthetic size (mm) $29/,29
Tricuspid valve operation Present/absent
Left auricular thrombectomy Present/absent
After this first screening, we tested various combinations of aortic and mitral physiopathologic anomalies (n 5 9) against the others. The same was done for
the different causes of valve disease, different types of valve operations, and different types of valve prostheses. AF, Atrial fibrillation; BSA, body surface area;
CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CT ratio, cardiothoracic ratio on chest x-ray films;
ECG LVH, ECG features of left ventricular hypertrophy; LVDEP, left ventricular end-diastolic pressure; LVDEVI, left ventricular end-diastolic volume index;
LVEF, left ventricular ejection fraction; NYHA class, New York Heart Association class; PAPm, mean pulmonary artery pressure; PAPs, systolic pulmonary
artery pressure; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure.
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